Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.

Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Sondermann W, Pul R, Kleinschnitz C, Wiendl H, Meuth SG, Klotz L.

Neurology. 2018 Nov 7. pii: 10.1212/WNL.0000000000006648. doi: 10.1212/WNL.0000000000006648. [Epub ahead of print]

PMID:
30404783
2.

Intubation, Tracheostomy and Decannulation in GBS-patients - does Dysphagia matter?

Schröder JB, Marian T, Muhle P, Claus I, Thomas C, Ruck T, Wiendl H, Warnecke T, Suntrup-Krueger S, Meuth S, Dziewas R.

Muscle Nerve. 2018 Nov 2. doi: 10.1002/mus.26377. [Epub ahead of print]

PMID:
30390307
3.

Human T cells in silico: Modelling dynamic intracellular calcium and its influence on cellular electrophysiology.

Eichinger P, Herrmann AM, Ruck T, Herty M, Gola L, Kovac S, Budde T, Meuth SG, Hundehege P.

J Immunol Methods. 2018 Oct;461:78-84. doi: 10.1016/j.jim.2018.06.020. Epub 2018 Jul 3.

PMID:
30158076
4.

Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.

Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, Kleinschnitz C, Kleiter I, Lee DH, Limmroth V, Mäurer M, Meuth S, Rieckmann P, Ruck T, Gold R, Linker RA.

J Neurol. 2018 Jul;265(7):1521-1527. doi: 10.1007/s00415-018-8871-2. Epub 2018 Apr 25.

PMID:
29696498
5.

Skeletal muscle cells actively shape (auto)immune responses.

Afzali AM, Müntefering T, Wiendl H, Meuth SG, Ruck T.

Autoimmun Rev. 2018 May;17(5):518-529. doi: 10.1016/j.autrev.2017.12.005. Epub 2018 Mar 9. Review.

PMID:
29526638
6.

[Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].

Meuth SG, Ruck T, Aktas O, Hartung HP.

Nervenarzt. 2018 Aug;89(8):895-907. doi: 10.1007/s00115-018-0498-0. Review. German.

PMID:
29523912
7.

Cytokine signaling in multiple sclerosis: Lost in translation.

Göbel K, Ruck T, Meuth SG.

Mult Scler. 2018 Apr;24(4):432-439. doi: 10.1177/1352458518763094. Epub 2018 Mar 7.

PMID:
29512406
8.

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study.

Riepl E, Pfeuffer S, Ruck T, Lohmann H, Wiendl H, Meuth SG, Johnen A.

Front Neurol. 2018 Jan 16;8:730. doi: 10.3389/fneur.2017.00730. eCollection 2017.

9.

Increase of Substance P Concentration in Saliva after Pharyngeal Electrical Stimulation in Severely Dysphagic Stroke Patients - an Indicator of Decannulation Success?

Muhle P, Suntrup-Krueger S, Bittner S, Ruck T, Claus I, Marian T, Schröder JB, Minnerup J, Warnecke T, Meuth SG, Dziewas R.

Neurosignals. 2017;25(1):74-87. doi: 10.1159/000482002. Epub 2017 Oct 17.

10.

An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function.

Kleffner I, Eichler S, Ruck T, Schüngel L, Pfeuffer S, Polzer P, Dittrich R, Dziewas R, Gross CC, Göbel K, Wiendl H, Kehrel BE, Meuth SG.

Front Neurol. 2017 Sep 28;8:517. doi: 10.3389/fneur.2017.00517. eCollection 2017.

11.

TRPC6 channels modulate the response of pancreatic stellate cells to hypoxia.

Nielsen N, Kondratska K, Ruck T, Hild B, Kovalenko I, Schimmelpfennig S, Welzig J, Sargin S, Lindemann O, Christian S, Meuth SG, Prevarskaya N, Schwab A.

Pflugers Arch. 2017 Dec;469(12):1567-1577. doi: 10.1007/s00424-017-2057-0. Epub 2017 Aug 28.

PMID:
28849300
12.

Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.

Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG.

Ther Adv Neurol Disord. 2017 Jan;10(1):51-66. doi: 10.1177/1756285616666741. Epub 2016 Sep 2. Review.

13.

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?

Krämer J, Tenberge JG, Kleiter I, Gaissmaier W, Ruck T, Heesen C, Meuth SG.

PLoS One. 2017 Apr 13;12(4):e0174858. doi: 10.1371/journal.pone.0174858. eCollection 2017.

14.

Nanomechanics of the endothelial glycocalyx contribute to Na+-induced vascular inflammation.

Schierke F, Wyrwoll MJ, Wisdorf M, Niedzielski L, Maase M, Ruck T, Meuth SG, Kusche-Vihrog K.

Sci Rep. 2017 Apr 13;7:46476. doi: 10.1038/srep46476.

15.

Recombinant tandem of pore-domains in a Weakly Inward rectifying K+ channel 2 (TWIK2) forms active lysosomal channels.

Bobak N, Feliciangeli S, Chen CC, Ben Soussia I, Bittner S, Pagnotta S, Ruck T, Biel M, Wahl-Schott C, Grimm C, Meuth SG, Lesage F.

Sci Rep. 2017 Apr 5;7(1):649. doi: 10.1038/s41598-017-00640-8.

16.

Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?

Afzali AM, Ruck T, Wiendl H, Meuth SG.

Autoimmun Rev. 2017 May;16(5):478-494. doi: 10.1016/j.autrev.2017.03.001. Epub 2017 Mar 7. Review.

17.

Isolated dysphagia as initial sign of anti-IgLON5 syndrome.

Schröder JB, Melzer N, Ruck T, Heidbreder A, Kleffner I, Dittrich R, Muhle P, Warnecke T, Dziewas R.

Neurol Neuroimmunol Neuroinflamm. 2016 Nov 22;4(1):e302. eCollection 2017 Jan.

18.

Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS.

Pfeuffer S, Beuker C, Ruck T, Lenze F, Wiendl H, Melzer N, Meuth SG.

Neurology. 2016 Nov 29;87(22):2380-2381. Epub 2016 Oct 28. No abstract available.

PMID:
27794114
19.

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

Gross CC, Ahmetspahic D, Ruck T, Schulte-Mecklenbeck A, Schwarte K, Jörgens S, Scheu S, Windhagen S, Graefe B, Melzer N, Klotz L, Arolt V, Wiendl H, Meuth SG, Alferink J.

Neurol Neuroimmunol Neuroinflamm. 2016 Oct 12;3(6):e289. eCollection 2016 Dec.

20.

14-3-3 Proteins regulate K2P 5.1 surface expression on T lymphocytes.

Fernández-Orth J, Ehling P, Ruck T, Pankratz S, Hofmann MS, Landgraf P, Dieterich DC, Smalla KH, Kähne T, Seebohm G, Budde T, Wiendl H, Bittner S, Meuth SG.

Traffic. 2017 Jan;18(1):29-43. doi: 10.1111/tra.12455. Epub 2016 Nov 27.

21.

The quality of cortical network function recovery depends on localization and degree of axonal demyelination.

Cerina M, Narayanan V, Göbel K, Bittner S, Ruck T, Meuth P, Herrmann AM, Stangel M, Gudi V, Skripuletz T, Daldrup T, Wiendl H, Seidenbecher T, Ehling P, Kleinschnitz C, Pape HC, Budde T, Meuth SG.

Brain Behav Immun. 2017 Jan;59:103-117. doi: 10.1016/j.bbi.2016.08.014. Epub 2016 Aug 25.

22.

The potassium channels TASK2 and TREK1 regulate functional differentiation of murine skeletal muscle cells.

Afzali AM, Ruck T, Herrmann AM, Iking J, Sommer C, Kleinschnitz C, Preuβe C, Stenzel W, Budde T, Wiendl H, Bittner S, Meuth SG.

Am J Physiol Cell Physiol. 2016 Oct 1;311(4):C583-C595. doi: 10.1152/ajpcell.00363.2015. Epub 2016 Aug 3.

23.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

24.

Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells.

Göbel K, Pankratz S, Asaridou CM, Herrmann AM, Bittner S, Merker M, Ruck T, Glumm S, Langhauser F, Kraft P, Krug TF, Breuer J, Herold M, Gross CC, Beckmann D, Korb-Pap A, Schuhmann MK, Kuerten S, Mitroulis I, Ruppert C, Nolte MW, Panousis C, Klotz L, Kehrel B, Korn T, Langer HF, Pap T, Nieswandt B, Wiendl H, Chavakis T, Kleinschnitz C, Meuth SG.

Nat Commun. 2016 May 18;7:11626. doi: 10.1038/ncomms11626.

25.

Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.

Pfeuffer S, Ruck T, Kleinschnitz C, Wiendl H, Meuth SG.

Expert Rev Neurother. 2016 Jun;16(6):689-700. doi: 10.1080/14737175.2016.1176531. Epub 2016 Apr 25. Review.

PMID:
27058174
26.

Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.

Obermann M, Ruck T, Pfeuffer S, Baum J, Wiendl H, Meuth SG.

Mult Scler. 2016 Aug;22(9):1235-41. doi: 10.1177/1352458516638558. Epub 2016 Mar 15. Review.

PMID:
26980848
27.

ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.

Ruck T, Afzali AM, Lukat KF, Eveslage M, Gross CC, Pfeuffer S, Bittner S, Klotz L, Melzer N, Wiendl H, Meuth SG.

BMC Neurol. 2016 Mar 10;16:34. doi: 10.1186/s12883-016-0556-9.

28.

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H.

J Neurol. 2016 Aug;263(8):1473-94. doi: 10.1007/s00415-016-8045-z. Epub 2016 Feb 17. Review.

29.

CD4(+)HLA-G(+) regulatory T cells: Molecular signature and pathophysiological relevance.

Pankratz S, Ruck T, Meuth SG, Wiendl H.

Hum Immunol. 2016 Sep;77(9):727-33. doi: 10.1016/j.humimm.2016.01.016. Epub 2016 Jan 27. Review.

PMID:
26826445
30.

The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies.

Ruck T, Bittner S, Afzali AM, Göbel K, Glumm S, Kraft P, Sommer C, Kleinschnitz C, Preuße C, Stenzel W, Wiendl H, Meuth SG.

Oncotarget. 2015 Dec 22;6(41):43230-43. doi: 10.18632/oncotarget.6462.

31.

Insights from mathematical modelling for T cell migration into the central nervous system.

Ruck T, Bittner S, Meuth SG, Herty M.

Math Med Biol. 2017 Mar 1;34(1):39-58. doi: 10.1093/imammb/dqv038.

PMID:
26519370
32.

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.

Dankowski T, Buck D, Andlauer TF, Antony G, Bayas A, Bechmann L, Berthele A, Bettecken T, Chan A, Franke A, Gold R, Graetz C, Haas J, Hecker M, Herms S, Infante-Duarte C, Jöckel KH, Kieseier BC, Knier B, Knop M, Kümpfel T, Lichtner P, Lieb W, Lill CM, Limmroth V, Linker RA, Loleit V, Meuth SG, Moebus S, Müller-Myhsok B, Nischwitz S, Nöthen MM, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Strauch K, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Waldenberger M, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Hemmer B, Ziegler A; German Competence Network for Multiple Sclerosis (KKNMS).

Genet Epidemiol. 2015 Dec;39(8):601-8. doi: 10.1002/gepi.21933. Epub 2015 Oct 26.

PMID:
26497834
33.

Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms.

Bittner S, Bobak N, Hofmann MS, Schuhmann MK, Ruck T, Göbel K, Brück W, Wiendl H, Meuth SG.

Int J Mol Sci. 2015 Jul 24;16(8):16880-96. doi: 10.3390/ijms160816880.

34.

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.

Ruck T, Bittner S, Wiendl H, Meuth SG.

Int J Mol Sci. 2015 Jul 20;16(7):16414-39. doi: 10.3390/ijms160716414. Review.

35.

Blood-brain barrier modeling: challenges and perspectives.

Ruck T, Bittner S, Meuth SG.

Neural Regen Res. 2015 Jun;10(6):889-91. doi: 10.4103/1673-5374.158342. No abstract available.

36.

Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis.

Deppe M, Marinell J, Krämer J, Duning T, Ruck T, Simon OJ, Zipp F, Wiendl H, Meuth SG.

Neuroimage Clin. 2014 Mar 3;6:475-87. doi: 10.1016/j.nicl.2014.02.012. eCollection 2014.

37.

Long-term efficacy of alemtuzumab in polymyositis.

Ruck T, Bittner S, Kuhlmann T, Wiendl H, Meuth SG.

Rheumatology (Oxford). 2015 Mar;54(3):560-2. doi: 10.1093/rheumatology/keu484. Epub 2014 Dec 30. No abstract available.

38.

Isolation of primary murine brain microvascular endothelial cells.

Ruck T, Bittner S, Epping L, Herrmann AM, Meuth SG.

J Vis Exp. 2014 Nov 14;(93):e52204. doi: 10.3791/52204.

39.

Effects of glatiramer acetate in a spontaneous model of autoimmune neuroinflammation.

Bittner S, Ruck T, Göbel K, Henschel C, Afzali AM, Göb E, Müntefering T, Kleinschnitz C, Wiendl H, Meuth SG.

Am J Pathol. 2014 Jul;184(7):2056-65. doi: 10.1016/j.ajpath.2014.03.009. Epub 2014 May 9.

PMID:
24819960
40.

Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis.

Göbel K, Schuhmann MK, Pankratz S, Stegner D, Herrmann AM, Braun A, Breuer J, Bittner S, Ruck T, Wiendl H, Kleinschnitz C, Nieswandt B, Meuth SG.

Eur J Immunol. 2014 Aug;44(8):2295-305. doi: 10.1002/eji.201344107. Epub 2014 Jun 5.

41.

Human CD4+ HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo.

Pankratz S, Bittner S, Herrmann AM, Schuhmann MK, Ruck T, Meuth SG, Wiendl H.

FASEB J. 2014 Aug;28(8):3435-45. doi: 10.1096/fj.14-251074. Epub 2014 Apr 17.

PMID:
24744146
42.

TREK-king the blood-brain-barrier.

Bittner S, Ruck T, Fernández-Orth J, Meuth SG.

J Neuroimmune Pharmacol. 2014 Jun;9(3):293-301. doi: 10.1007/s11481-014-9530-8. Epub 2014 Feb 21. Review.

PMID:
24557892
43.

Long-term effects of dalfampridine in patients with multiple sclerosis.

Ruck T, Bittner S, Simon OJ, Göbel K, Wiendl H, Schilling M, Meuth SG.

J Neurol Sci. 2014 Feb 15;337(1-2):18-24. doi: 10.1016/j.jns.2013.11.011. Epub 2013 Nov 16.

PMID:
24290498
44.

CD4+NKG2D+ T cells exhibit enhanced migratory and encephalitogenic properties in neuroinflammation.

Ruck T, Bittner S, Gross CC, Breuer J, Albrecht S, Korr S, Göbel K, Pankratz S, Henschel CM, Schwab N, Staszewski O, Prinz M, Kuhlmann T, Meuth SG, Wiendl H.

PLoS One. 2013 Nov 25;8(11):e81455. doi: 10.1371/journal.pone.0081455. eCollection 2013.

45.

DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis.

Deppe M, Müller D, Kugel H, Ruck T, Wiendl H, Meuth SG.

Neuroimage Clin. 2013 Jan 28;2:258-62. doi: 10.1016/j.nicl.2013.01.008. eCollection 2013.

46.

Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS.

Bittner S, Ruck T, Schuhmann MK, Herrmann AM, Moha ou Maati H, Bobak N, Göbel K, Langhauser F, Stegner D, Ehling P, Borsotto M, Pape HC, Nieswandt B, Kleinschnitz C, Heurteaux C, Galla HJ, Budde T, Wiendl H, Meuth SG.

Nat Med. 2013 Sep;19(9):1161-5. doi: 10.1038/nm.3303. Epub 2013 Aug 11.

PMID:
23933981
47.

Active immunization with proteolipid protein (190-209) induces ascending paralysing experimental autoimmune encephalomyelitis in C3H/HeJ mice.

Göbel K, Bittner S, Ruck T, Budde T, Wischmeyer E, Döring F, Wiendl H, Meuth SG.

J Immunol Methods. 2011 Mar 31;367(1-2):27-32. doi: 10.1016/j.jim.2010.12.018. Epub 2010 Dec 31.

PMID:
21199659
48.

FOXP3+ T regulatory cells in idiopathic inflammatory myopathies.

Waschbisch A, Schwab N, Ruck T, Stenner MP, Wiendl H.

J Neuroimmunol. 2010 Aug 25;225(1-2):137-42. doi: 10.1016/j.jneuroim.2010.03.013.

PMID:
20537411
49.

Microemulsions with an ionic liquid surfactant and room temperature ionic liquids as polar pseudo-phase.

Zech O, Thomaier S, Bauduin P, Rück T, Touraud D, Kunz W.

J Phys Chem B. 2009 Jan 15;113(2):465-73. doi: 10.1021/jp8061042.

PMID:
19099438

Supplemental Content

Support Center